[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 39 of about 39
1. Gimbel MI, Delman KA, Zager JS: Therapy for unresectable recurrent and in-transit extremity melanoma. Cancer Control; 2008 Jul;15(3):225-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy for unresectable recurrent and in-transit extremity melanoma.
  • This represents late-stage disease for which curative treatment options are limited.
  • METHODS: To review the current treatment strategies for stage IIIB (N2c) in-transit and recurrent melanoma focusing on the options for unresectable disease, MEDLINE was searched for studies of known and experimental treatments for in-transit and recurrent extremity melanoma.
  • RESULTS: For unresectable recurrences and in-transit metastases, therapies are limited to palliative (radiation), local (intratumoral injection, laser ablation and electroporation), regional (isolated limb perfusion/infusion), and systemic (chemotherapy) when local or regional techniques are not feasible.
  • CONCLUSIONS: In this patient population, intratumoral techniques have a limited role with current treatment regimens, but with the development of new drugs, these techniques may have more utility.
  • Until new regimens are available, systemic therapy continues to be associated with considerable toxicity and only marginal response rates.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Electroporation / methods. Laser Therapy / methods. Melanoma / therapy. Neoplasm Recurrence, Local / surgery. Skin Neoplasms / therapy
  • [MeSH-minor] Humans. Leg. Neoplasm Staging. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18596674.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 83
  •  go-up   go-down


2. van Ginkel RJ, Thijssens KM, Pras E, van der Graaf WT, Suurmeijer AJ, Hoekstra HJ: Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation. Ann Surg Oncol; 2007 Apr;14(4):1499-506
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb perfusion with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma: three time periods at risk for amputation.
  • BACKGROUND: The aim of this study was to investigate the long-term limb salvage rate and overall survival after isolated limb perfusion (ILP) with tumor necrosis factor alpha and melphalan for locally advanced soft tissue sarcoma (STS).
  • We found that the risk of amputation was linked to three time periods.
  • The first was within a year after perfusion, mainly as a result of massive necrosis of the tumor and overlying skin, resulting in soft tissue deficit or recurrent disease (n = 17).
  • The third occurred 10 years after perfusion, with two amputations performed for critical leg ischemia.
  • Another two patients developed a pathological fracture of the femur due to radiation osteonecrosis.
  • CONCLUSIONS: ILP treatment with tumor necrosis factor alpha and melphalan followed by delayed surgical resection and adjuvant radiation treatment is an effective limb salvage treatment regimen for locally advanced STS.
  • However, we observed late morbidity, with two amputations performed for critical leg ischemia and two pathological fractures of the femur in patients receiving adjuvant radiotherapy.
  • [MeSH-major] Amputation. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Melphalan / administration & dosage. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Risk Factors. Survival Rate. Tumor Necrosis Factor-alpha / administration & dosage

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):745-50 [11020571.001]
  • [Cites] Cancer. 1989 Aug 1;64(3):616-21 [2743257.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):792-7 [11087648.001]
  • [Cites] Ann Surg Oncol. 2002 May;9(4):355-63 [11986187.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2235-41 [12103287.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1117-27 [12829150.001]
  • [Cites] Cancer. 2003 Oct 1;98(7):1483-90 [14508836.001]
  • [Cites] Radiology. 1971 Nov;101(2):429-33 [5114783.001]
  • [Cites] Br J Radiol. 1974 Feb;47(554):157-8 [4817460.001]
  • [Cites] Radiat Res. 1975 Jul;63(1):157-64 [1144676.001]
  • [Cites] Ann Surg. 1977 May;185(5):555-64 [266397.001]
  • [Cites] Ann Surg. 1980;192(4):431-8 [6932827.001]
  • [Cites] Cancer. 1981 May 1;47(9):2269-74 [7226121.001]
  • [Cites] Ann Surg. 1982 Sep;196(3):305-15 [7114936.001]
  • [Cites] Cancer. 1984 Jun 15;53(12):2579-84 [6372980.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Am J Surg. 1988 May;155(5):667-71 [3369621.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1485-92 [1938557.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):52-60 [1727926.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2140-6 [8156518.001]
  • [Cites] Arch Surg. 1995 Jan;130(1):43-7 [7802575.001]
  • [Cites] Ann Surg Oncol. 1994 Sep;1(5):382-8 [7850539.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Jul 30;32(5):1289-300 [7635768.001]
  • [Cites] Arch Surg. 1996 Jun;131(6):672-4 [8645079.001]
  • [Cites] Crit Care Med. 1996 May;24(5):765-70 [8706451.001]
  • [Cites] Eur J Surg Oncol. 1996 Oct;22(5):528-31 [8903498.001]
  • [Cites] Ann Surg. 1996 Dec;224(6):756-64; discussion 764-5 [8968230.001]
  • [Cites] Cancer. 1997 Mar 15;79(6):1129-37 [9070490.001]
  • [Cites] Lancet. 1997 Dec 6;350(9092):1647-54 [9400508.001]
  • [Cites] Clin Orthop Relat Res. 1998 Jul;(352):168-78 [9678045.001]
  • [Cites] Cancer Treat Rev. 1998 Dec;24(6):373-91 [10189405.001]
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] J Clin Oncol. 2006 Feb 1;24(4):619-25 [16446334.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):669-78 [11078614.001]
  • (PMID = 17253101.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  • [Other-IDs] NLM/ PMC1914273
  •  go-up   go-down


3. Quéreux G, Renaut JJ, Peuvrel L, Knol AC, Brocard A, Dréno B: Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: role of immunosuppressants. Acta Derm Venereol; 2010 Nov;90(6):616-20
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The 36-year-old patient, who had previously been treated successively with methotrexate, ciclosporin and etanercept, presented with rapidly growing nodules on the leg.
  • Despite treatment with pegylated liposomal doxorubicin, the disease progressed and the patient died 5 months later.
  • The onset of this disease in a patient with psoriasis who had been previously treated with immunosuppressive drugs and a tumour necrosis factor (TNF)-α blocker is of major interest.
  • Only eight cases of cutaneous lymphomas associated with treatment with TNF-α blockers have been published previously.
  • [MeSH-major] Immunosuppressive Agents / adverse effects. Lymphoma, T-Cell, Cutaneous / chemically induced. Psoriasis / drug therapy. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antibiotics, Antineoplastic / therapeutic use. Biopsy. Cyclosporine / adverse effects. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Etanercept. Fatal Outcome. Humans. Immunoglobulin G / adverse effects. Leg. Male. Methotrexate / adverse effects. Neoplasm Invasiveness. Neoplasm Staging. Polyethylene Glycols / therapeutic use. Receptors, Tumor Necrosis Factor. Treatment Failure

  • Genetic Alliance. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Psoriasis.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Etanercept .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057746.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Immunoglobulin G; 0 / Immunosuppressive Agents; 0 / Receptors, Tumor Necrosis Factor; 0 / liposomal doxorubicin; 30IQX730WE / Polyethylene Glycols; 80168379AG / Doxorubicin; 83HN0GTJ6D / Cyclosporine; OP401G7OJC / Etanercept; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


Advertisement
4. Grandpeix C, Bonvalot S, Petrow P, Fraitag S, Gounod N, Avril MF: [Continued complete remission of Merkel cell carcinoma with in-transit metastasis after treatment with isolated limb perfusion regional chemotherapy]. Ann Dermatol Venereol; 2006 Aug-Sep;133(8-9 Pt 1):700-3
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Continued complete remission of Merkel cell carcinoma with in-transit metastasis after treatment with isolated limb perfusion regional chemotherapy].
  • [Transliterated title] Rémission complète persistante d'une tumeur de Merkel avec métastases satellites après traitement par chimiothérapie locorégionale de type membre perfusé isolé.
  • It may be large since diagnosis is frequently delayed.
  • The usual treatment is extensive surgical removal and radiotherapy.
  • PATIENTS AND METHODS: A 69-year-old woman presented with a large Merkel cell carcinoma of the right leg.
  • Regional chemotherapy involving isolated limb perfusion with melphalan was performed in order to avoid amputation.
  • Only one patient was still in complete remission 18 months after treatment.
  • Isolated limb perfusion chemotherapy could thus be indicated in the treatment of advanced Merkel cell carcinoma of a limb in the absence of bone or regional lymph node involvement.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Chemotherapy, Cancer, Regional Perfusion. Leg. Melphalan / therapeutic use. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Ankle Joint / physiopathology. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Pigmentation Disorders / etiology. Range of Motion, Articular / physiology. Remission Induction. Sclerosis. Skin / pathology

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17053743.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


5. Nomura E, Isoda K, Yamanaka K, Yamaguchi M, Hakamada A, Mizutani H: Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy. J Dermatol; 2005 Mar;32(3):204-9
Hazardous Substances Data Bank. DEXAMETHASONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy.
  • We report a 76-year-old woman with extra nodal NK/T-cell lymphoma nasal type (ENKL).
  • She had large tumors on her left leg with inguinal lymphadenopathy and gastric tumors.
  • Immunohistologically, the tumor cells from the skin lesion expressed CD2, cytoplasmic CD3, CD56, and T-cell intracellular antigen-1 (TIA-1), but not surface CD3, CD19, and TdT.
  • The tumors responded remarkably well to radiation therapy followed by multi-drug resistance independent DeVIC (carboplatin, etoposide, ifosfamide, and dexamethasone) combination therapy.
  • After two series of this therapy, no tumors were detected in clinical, histopathological, endoscope and computerized tomogram (CT) examinations.
  • Although there may be a limitation of effects on metastasis of tumors in the central nervous system, radiation and DeVIC combination therapy is a potent therapeutic method for ENKL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / therapy. Neoplasm Invasiveness / pathology. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Aged. Biopsy, Needle. Carboplatin / therapeutic use. Combined Modality Therapy. Dexamethasone / therapeutic use. Disease Progression. Etoposide / therapeutic use. Fatal Outcome. Female. Humans. Ifosfamide / therapeutic use. Immunohistochemistry. Killer Cells, Natural / pathology. Neoplasm Staging. Radiotherapy, Adjuvant

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863868.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


6. Neumann A, Karbach J, Atmaca A, Jäger E: [Long-term remission of malignant melanoma stage IV after antigen-specific immunotherapy]. Med Klin (Munich); 2010 Apr;105(4):273-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This case report describes the clinical course of a patient with progressing metastatic melanoma (M1a) under standard chemotherapy, followed by long-term partial remission of disease under treatment with experimental, specific immunotherapy.
  • [MeSH-major] Antigens, Neoplasm / immunology. Cancer Vaccines / therapeutic use. Epitopes / immunology. Immunotherapy / methods. Leg. Melanoma / drug therapy. Neoplasm Proteins / immunology. Skin Neoplasms / drug therapy. Survivors
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. CD4-Positive T-Lymphocytes / drug effects. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / drug effects. CD8-Positive T-Lymphocytes / immunology. Chemotherapy, Adjuvant. Disease Progression. Female. Follow-Up Studies. Humans. Hypersensitivity, Delayed / immunology. Injections, Intradermal. Lymphatic Metastasis / pathology. Melanoma-Specific Antigens. Middle Aged. Neoplasm Staging. Palliative Care

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2000 May 15;86(4):538-47 [10797269.001]
  • [Cites] Int J Cancer. 1996 Jul 3;67(1):54-62 [8690525.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 26;103(39):14453-8 [16984998.001]
  • [Cites] Cancer Sci. 2009 Nov;100(11):2014-21 [19719775.001]
  • [Cites] J Exp Med. 1996 Mar 1;183(3):725-9 [8642276.001]
  • (PMID = 20455048.001).
  • [ISSN] 1615-6722
  • [Journal-full-title] Medizinische Klinik (Munich, Germany : 1983)
  • [ISO-abbreviation] Med. Klin. (Munich)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines; 0 / Epitopes; 0 / Melanoma-Specific Antigens; 0 / Neoplasm Proteins
  •  go-up   go-down


7. Mahieu-Renard L, Richard MA, Dales JP, Buscaylet S, Lagrassa S, Grob JJ: [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine]. Ann Dermatol Venereol; 2005 Apr;132(4):346-8
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
  • [Transliterated title] Traitement de métastases cutanées d'un carcinome épidermoïde de la jambe par applications de miltéfosine.
  • INTRODUCTION: Miltefosine (Hexadecylphosphocholine) is a chemotherapy, which when applied locally, has demonstrated efficacy in the treatment of cutaneous metastases of breast cancer.
  • CASE REPORT: A 79 year-old woman developed recurrent in transit cutaneous metastases of a squamous cell carcinoma on her left leg.
  • Tolerance was excellent and the patient remained disease-free 24 months after the end of the treatment.
  • DISCUSSION: Miltefosine, which might prove to be a simple and effective alternative for the usually heavy treatments proposed, warrants further assessment in this context.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Neoplasm Recurrence, Local / drug therapy. Phosphorylcholine / analogs & derivatives. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary
  • [MeSH-minor] Administration, Topical. Aged. Female. Humans. Leg

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15886562.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 107-73-3 / Phosphorylcholine; 53EY29W7EC / miltefosine
  •  go-up   go-down


8. Iacobellis C, Olmeda A: The Ilizarov method in the treatment of malignant neoplasms of the tibia. Chir Organi Mov; 2004 Jul-Aug;89(3):245-50
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Ilizarov method in the treatment of malignant neoplasms of the tibia.
  • A total of 3 malignant neoplasms of the tibia are presented: 1 is a mesenchymal chondrosarcoma of the tibial pylon (male aged 14 years), and 2 are cases of squamous skin carcinoma of the leg with tibial infiltration (1 male and 1 female aged 32 and 64 years, respectively).
  • The regenerate obtained was slowly corticalized in the first patient, submitted to various cycles of chemotherapy during the course of distraction.
  • In the other two cases, which were not treated by chemotherapy during distraction, corticalization occurred over a shorter amount of time.
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Arthrodesis. Bone Transplantation. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Osteogenesis, Distraction. Osteotomy. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology. Time Factors. Transplantation, Autologous. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751591.001).
  • [ISSN] 0009-4749
  • [Journal-full-title] La Chirurgia degli organi di movimento
  • [ISO-abbreviation] Chir Organi Mov
  • [Language] eng; ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


9. Lejeune FJ, Pujol N, Liénard D, Mosimann F, Raffoul W, Genton A, Guillou L, Landry M, Chassot PG, Chiolero R, Bischof-Delaloye A, Leyvraz S, Mirimanoff RO, Bejkos D, Leyvraz PF: Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. Eur J Surg Oncol; 2000 Nov;26(7):669-78
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities.
  • AIMS: Patients with non-resectable soft tissue sarcomas of the extremities do not live longer if they are treated by amputation or disarticulation.
  • In order to avoid major amputations, we tested isolated limb perfusion (ILP) with tumour necrosis factor alpha (TNF)+melphalan+/-interferon-gamma (IFN) as a pre-operative, neoadjuvant limb salvage treatment.
  • METHODS: Twenty-two patients were included (six men and 16 women; three upper limb and 19 lower limb tumours).
  • Thirteen cases were recurrent or progressive after previous therapy; five tumours had a diameter >/=20 cm, and four were multiple or regionally metastatic.
  • All patients had fever for 24 hours but only one developed a reversible grade 3 distributive shock syndrome with no sequelae.
  • Seventeen patients (77%) underwent limb-sparing resection of the tumour remnants after a median time of 3.4 months: 10 resections were intracompartmental and seven extracompartmental.
  • Surgery included flaps or skin grafts in five patients, arterial replacement in two and knee arthrodesis in one.
  • Adjuvant chemotherapy was given to eight patients and radiotherapy to six.
  • The median disease free and overall survival times have been >12.5 and 18.7 months respectively: this is similar to the outcome after primary amputations for similar cases.
  • CONCLUSION: ILP with TNF and chemotherapy is an efficient limb sparing neoadjuvant therapy for a priori non-resectable limb soft tissue sarcomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Leg / surgery. Sarcoma / drug therapy. Sarcoma / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Chemotherapy, Cancer, Regional Perfusion. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Interferon-gamma / administration & dosage. Interferon-gamma / adverse effects. Male. Melphalan / administration & dosage. Melphalan / adverse effects. Middle Aged. Neoadjuvant Therapy. Neoplasm Recurrence, Local / surgery. Radiotherapy, Adjuvant. Salvage Therapy. Survival Analysis. Tumor Necrosis Factor-alpha / administration & dosage. Tumor Necrosis Factor-alpha / adverse effects

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Harcourt Publishers Ltd.
  • (PMID = 11078614.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; 80168379AG / Doxorubicin; 82115-62-6 / Interferon-gamma; Q41OR9510P / Melphalan; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


10. Dürr HR, Pellengahr C, Nerlich A, Baur A, Maier M, Jansson V: Stewart-Treves syndrome as a rare complication of a hereditary lymphedema. Vasa; 2004 Feb;33(1):42-5
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A case of LAS in hereditary lymphedema of the lower extremity in a 36-year old female is reported.
  • Despite of chemotherapy, local hyperthermia and later amputation of the extremity the patient died of progressive disease due to pulmonary metastasis.
  • In respect to this case, the different therapeutic concepts, as reported in the literature, and their results are presented and discussed.
  • [MeSH-major] Leg. Lymphangiosarcoma / diagnosis. Lymphedema / complications. Lymphedema / genetics. Skin Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Amputation. Antigens, CD31 / analysis. Biopsy. Disease Progression. Fatal Outcome. Female. Genes, Dominant. Genetic Predisposition to Disease / genetics. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness / pathology. Skin / pathology. Syndrome

  • Genetic Alliance. consumer health - Lymphedema.
  • Genetic Alliance. consumer health - Stewart Treves syndrome.
  • MedlinePlus Health Information. consumer health - Lymphedema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15061047.001).
  • [ISSN] 0301-1526
  • [Journal-full-title] VASA. Zeitschrift für Gefässkrankheiten
  • [ISO-abbreviation] VASA
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD31
  •  go-up   go-down


11. Ueno S, Yokoyama S, Hirakawa H, Yabe H, Suzuki Y, Atsumi H, Matsumae M: Use of real-time magnetic resonance guidance to assist bone biopsy in pediatric malignancy. Pediatrics; 2002 Jan;109(1):E18
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of real-time magnetic resonance guidance to assist bone biopsy in pediatric malignancy.
  • We present a case involving pediatric malignancy where MR-guided bone biopsy confirmed correct histologic diagnosis and was used to plan additional treatment.
  • A 2-year, 9-month-old boy had a history of spontaneous regression of stage 4S neuroblastoma. (123)I-metaiodobenzylguanidine scintigraphy showed a hot spot at his right lower leg; however, neither plain radiograph (99m)Tc diphosphonate bone scan was positive.
  • Only MRI depicted a lesion at the distal third of his right tibia, and a subsequent MR-guided bone biopsy was diagnostic of bone marrow metastasis.
  • After 6 courses of intensive chemotherapy, he has been in complete remission.
  • [MeSH-major] Bone Neoplasms / pathology. Bone Neoplasms / secondary. Magnetic Resonance Imaging / methods. Neuroblastoma / diagnosis. Neuroblastoma / secondary
  • [MeSH-minor] Adrenal Gland Neoplasms / pathology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Biopsy / methods. Child, Preschool. Humans. Liver Neoplasms / secondary. Male. Neoplasm Regression, Spontaneous. Remission Induction / methods. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11773586.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


12. El-Helw L, Goodwin S, Slater D, Hancock BW: Primary B-cell lymphoma of the skin: the Sheffield Lymphoma Group Experience (1984-2003). Int J Oncol; 2004 Nov;25(5):1453-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary B-cell lymphoma of the skin: the Sheffield Lymphoma Group Experience (1984-2003).
  • The clinical presentation, treatment and outcome were retrospectively evaluated in a series of 66 patients with primary B-cell lymphoma of the skin, referred to the Sheffield lymphoma group (SLG) between 1984 and 2003.
  • The most commonly involved site was the trunk and the disorder typically showed non-aggressive clinical behaviour; the majority of the patients presented with stage I (82%) disease with a tendency to remain localised to a limited area of the skin.
  • The majority (47%) of patients were treated with radiotherapy for localised disease whereas chemotherapy was given in 20% of patients, with single agent chlorambucil being most frequently used.
  • Surgical excision as the sole modality of treatment was adequate in 33%.
  • DFS was significantly lower with older age (>45 years), leg lesions, generalised and multiple lesions, and for those treated with chemotherapy.
  • The histologic grade, leg involvement and the number of lesions were the most significant variables affecting overall survival.
  • In conclusion, primary cutaneous B-cell lymphoma represents a specific entity concerning clinical behaviour, response to treatment, and overall prognosis.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiotherapy. Skin Neoplasms / pathology. Skin Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Aged, 80 and over. Antigens, Neoplasm / biosynthesis. Databases, Factual. Disease-Free Survival. Female. Great Britain. Humans. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15492838.001).
  • [ISSN] 1019-6439
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, Neoplasm
  •  go-up   go-down


13. Nicolas C, Reichert-Penetrat S, Granel F, Barbaud A, Schmutz JL: [Ultra-late metastasis of melanoma with secondary dissemination along the venous stripping line]. Ann Dermatol Venereol; 2000 Jan;127(1):60-3
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: A woman was cured of a melanoma of the leg.
  • She was then given chemotherapy and BCGtherapy for 2 years.
  • In March 1997, she underwent a stripping of the leg.
  • [MeSH-major] Melanoma / secondary. Neoplasm Metastasis. Postoperative Complications. Saphenous Vein / surgery. Skin Neoplasms / pathology. Thrombophlebitis / surgery
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Leg. Lymphatic Metastasis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Time Factors

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10717565.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] FRANCE
  •  go-up   go-down


14. Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG, Italian Study Group for Cutaneous Lymphomas: Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol; 2006 Mar 20;24(9):1376-82
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All of the patients were reclassified according to the WHO-European Organisation for Research and Treatment of Cancer (EORTC) classification.
  • RESULTS: Follicle center lymphoma (FCL) accounted for 56.7% of occurrences, followed by marginal-zone B-cell lymphoma (MZL; 31.4%); diffuse large B-cell lymphoma (DLBCL), leg type, was reported in 10.9% of patients.
  • Radiotherapy was the first-line treatment in 52.5% of patients and chemotherapy was the first-line treatment in 24.8% of patients.
  • Compared with FCL/MZL, DLBCL, leg type, was characterized by statistically significant lower complete response rates, higher incidence of multiple cutaneous relapses and extracutaneous spreading, shorter time to progression, and shorter OS rates.
  • The only variable with independent prognostic significance on the OS was the clinicopathologic diagnosis according to the WHO-EORTC classification (DLBCL, leg-type, showed a significantly worse prognosis v FCL and MZL; P < .001), whereas the only variable with independent prognostic significance on disease-free survival was the presence of a single cutaneous lesion (P = .001).
  • [MeSH-major] Lymphoma, B-Cell / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous B-Cell Lymphomas.
  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Aug 20;24(24):4041; author reply 4041-2 [16921065.001]
  • (PMID = 16492713.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


15. Anghel G, Petrinato G, Severino A, Remotti D, Insabato L, De Renzo A, Rotoli B, Majolino I: Intravascular B-cell lymphoma: report of two cases with different clinical presentation but rapid central nervous system involvement. Leuk Lymphoma; 2003 Aug;44(8):1353-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Intravascular lymphomatosis (IVL) is a rare large-cell lymphoproliferative disorder characterized by a widespread lymphoma proliferation within the lumen of medium and small vessels, frequently presenting with skin and/or central nervous system (CNS) manifestations.
  • The first was that of a 55-year-old woman with a large B-cell lymphoma of the leg, successfully treated with conventional chemotherapy (CHT) followed by autologous peripheral stem cell transplantation.
  • She died before any specific treatment, and post-mortem examination revealed the intravascular proliferation of lymphoma B-cells in the brain and bone marrow.
  • The second case was that of a 60-year-old male with CNS involvement at diagnosis.
  • He responded poorly to CHOP-like CHT, and died 2 months after diagnosis and 6 months after onset of symptoms.
  • Failure of CHT at least in some IVL patients may be related to a delay in the initiation of therapy due to non-specific neurological symptoms.
  • Therefore, early diagnosis based upon aggressive attempts immediately followed by adequate therapy may prove beneficial to these patients.
  • [MeSH-minor] Autopsy. Fatal Outcome. Female. Humans. Leg / blood supply. Male. Middle Aged. Neoplasm Invasiveness / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12952229.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 38
  •  go-up   go-down


16. Chen YF, Li YC, Chen LM, Tu CC, Chang CC, Kuo SY, Lin SH, Chuang SS: Primary cutaneous diffuse large B cell lymphoma relapsed solely as a huge lung tumor mimicking a primary pulmonary lymphoma. Int J Hematol; 2010 Jan;91(1):112-6
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary cutaneous large B cell lymphoma, leg type (PCLBCL-leg) has recently been identified and recognized as a specific entity.
  • Patients with PCLBCL-leg have a higher relapse rate and a poorer prognosis than the other types of primary cutaneous B cell lymphomas, and disease relapse is confined to the skin in the majority of cases with rare exclusive extracutaneous progression.
  • The distinction is of important clinical and therapeutic implications.
  • Here, we report the case of a 90-year-old lady with a history of PCLBCL-leg in complete remission after radiotherapy that developed a huge, solitary pulmonary lymphoma without lymphadenopathy 14 months later.
  • The latter was initially considered as stage IE primary pulmonary lymphoma and was treated with combination chemotherapy resulting in complete remission.
  • Retrospective pathologic review and B cell clonality study revealed that the pulmonary tumor was a diffuse large B cell lymphoma of the same clonal origin as the PCLBCL-leg.
  • [MeSH-major] Lung Neoplasms / pathology. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Biopsy. Clone Cells / pathology. Diagnosis, Differential. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Radiography

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2004 Jan 1;103(1):275-82 [14504078.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] Arch Pathol Lab Med. 2010 Jul;134(7):996-1002 [20586627.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2009 Jan;17(1):77-81 [19115486.001]
  • [Cites] Ann Hematol. 2009 Sep;88(9):839-46 [19139892.001]
  • [Cites] Br J Haematol. 2002 Sep;118(3):809-12 [12181049.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Curr Opin Oncol. 2006 Sep;18(5):425-31 [16894288.001]
  • [Cites] Leuk Lymphoma. 2003 Jan;44(1):117-21 [12691150.001]
  • [Cites] Radiat Med. 2000 Nov-Dec;18(6):369-75 [11153690.001]
  • [Cites] Am J Surg Pathol. 2002 Jan;26(1):76-81 [11756772.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):757-62 [8616769.001]
  • [Cites] Jpn J Clin Oncol. 2004 Sep;34(9):510-4 [15466823.001]
  • [Cites] Leuk Lymphoma. 2004 Aug;45(8):1539-43 [15370204.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1376-82 [16492713.001]
  • [Cites] Eur J Immunol. 1999 Apr;29(4):1253-64 [10229093.001]
  • [Cites] Am J Surg Pathol. 2003 Dec;27(12):1538-45 [14657713.001]
  • [Cites] Leuk Lymphoma. 2006 Jun;47(6):1144-8 [16840208.001]
  • [Cites] Arch Dermatol. 1996 Nov;132(11):1304-8 [8915307.001]
  • (PMID = 20012513.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


17. Fink W, Zimpfer A, Ugurel S: Mucosal metastases in malignant melanoma. Onkologie; 2003 Jun;26(3):249-51
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 38-year-old male patient with metastatic malignant melanoma of stage III (AJCC) was admitted for initiation of adjuvant therapy.
  • 4 months earlier a primary melanoma of the left upper leg had been excised and 2 months later the patient had undergone a left inguinal lymph node dissection revealing 2 metastatic lymph nodes.
  • Two cycles of dacarbazine (DTIC) chemotherapy were performed during which the patient developed cutaneous metastases, dyspepsia, and mild hematemesis.
  • A few weeks later the patient developed macroscopic hematuria.
  • [MeSH-major] Esophageal Neoplasms / secondary. Melanoma / secondary. Skin Neoplasms / pathology. Stomach Neoplasms / secondary. Tonsillar Neoplasms / secondary. Urinary Bladder Neoplasms / secondary
  • [MeSH-minor] Adult. Combined Modality Therapy. Diagnosis, Differential. Gastric Mucosa / pathology. Humans. Male. Mucous Membrane / pathology. Neoplasm Staging. Tomography, Emission-Computed


18. Busam KJ, Hester K, Charles C, Sachs DL, Antonescu CR, Gonzalez S, Halpern AC: Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy. Arch Dermatol; 2001 Jul;137(7):923-9
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of clinically amelanotic malignant melanoma and assessment of its margins by in vivo confocal scanning laser microscopy.
  • BACKGROUND: Near-infrared confocal scanning laser microscopy (CSLM) represents a novel imaging technique for in vivo microscopic analysis of skin lesions, including pigmented lesions.
  • Sites suspected to represent melanoma or benign skin on CSLM were marked as such; then, biopsy specimens were obtained for diagnosis using conventional histological analysis.
  • RESULTS: The images obtained using CSLM allowed recognition of an abnormal intraepidermal melanocytic proliferation that was distinctly different from normal skin.
  • Comparison of the sites examined using CSLM and subsequently using conventional histological methods revealed that CSLM correctly identified intraepidermal melanoma and benign skin.
  • CONCLUSIONS: We demonstrated, for the first time, the detection of clinically amelanotic melanoma using CSLM.
  • This technique may aid in the early detection of clinically barely visible or nonpigmented melanomas and may facilitate preoperative noninvasive assessment of their margins.
  • [MeSH-major] Melanoma, Amelanotic / diagnosis. Microscopy, Confocal. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biopsy. Cheek. Female. Humans. Immunohistochemistry. Infrared Rays. Leg. Melanosomes / pathology. Microscopy, Electron. Neoplasm Invasiveness. Neoplasm Staging. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11453812.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Zhao J, Han B, Shen T, Zhao Y, Wang T, Liu Y, Fang K, Zhong D, Ling Q: Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature. Int J Hematol; 2009 Jan;89(1):113-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous diffuse large B-cell lymphoma (leg type) after renal allograft: case report and review of the literature.
  • We report a case of a 58-year-old man who presented with a rapidly growing proliferative lesion on the left lower limb, clinically resembling a soft tissue sarcoma 3 years after renal allograft.
  • There was no evidence of systemic involvement on bone marrow needle aspiration and computed tomography (CT) scans of the chest and abdomen.
  • The lesion turned out to be primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL LT), as defined in the recent World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification of cutaneous lymphomas by skin biopsy.
  • Immunosuppression reduction, chemotherapy with CHOP regimen and local radiotherapy induced complete remission of the tumor.
  • [MeSH-minor] Humans. Leg / pathology. Male. Middle Aged. Neoplasm Invasiveness. Remission Induction / methods. Skin Neoplasms / etiology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3602-10 [11504742.001]
  • [Cites] Pediatr Transplant. 2005 Oct;9(5):622-6 [16176420.001]
  • [Cites] J Cardiovasc Pharmacol Ther. 2006 Mar;11(1):77-83 [16703222.001]
  • [Cites] Arch Dermatol. 2004 Sep;140(9):1140-6 [15381556.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Clin Transplant. 2005 Oct;19(5):668-73 [16146560.001]
  • [Cites] Br J Dermatol. 2005 Nov;153(5):874-80 [16225594.001]
  • [Cites] Transplant Proc. 2006 Mar;38(2):641-5 [16549195.001]
  • [Cites] Transplant Proc. 2007 May;39(4):1071-3 [17524894.001]
  • [Cites] Clin Transplant. 2005 Jun;19(3):327-34 [15877793.001]
  • [Cites] Am J Transplant. 2006 Nov;6(11):2735-42 [17049061.001]
  • [Cites] Am J Clin Pathol. 2002 Apr;117(4):574-80 [11939732.001]
  • [Cites] Arch Dermatol. 2007 Sep;143(9):1144-50 [17875875.001]
  • [Cites] Transplantation. 2005 Sep 15;80(5):595-9 [16177631.001]
  • [Cites] Transplant Proc. 2006 Oct;38(8):2448-50 [17097963.001]
  • [Cites] Blood. 2002 Feb 1;99(3):800-5 [11806979.001]
  • [Cites] J Cutan Pathol. 2005 Nov;32(10):647-74 [16293178.001]
  • [Cites] Transplantation. 2006 Mar 27;81(6):888-95 [16570013.001]
  • [Cites] Arch Dermatol. 2005 Sep;141(9):1139-45 [16172311.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1065-70 [16957512.001]
  • [Cites] Transplantation. 2005 Jul 27;80(2):193-7 [16041263.001]
  • (PMID = 19109733.001).
  • [ISSN] 1865-3774
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 21
  •  go-up   go-down


20. Stokkermans-Dubois J, Jouary T, Vergier B, Delaunay MM, Taieb A: A case of primary cutaneous nasal type NK/T-cell lymphoma and review of the literature. Dermatology; 2006;213(4):345-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of primary cutaneous nasal type NK/T-cell lymphoma and review of the literature.
  • This article describes a new case of primary cutaneous natural killer/T-cell lymphoma of nasal type (NKTL-NT) and reviews 18 other cases of this rare neoplasm.
  • CASE REPORT: A 79-year-old man presented with a 3-cm nodular tumor of the left leg occurring on a primary chronic lymphedema of the legs.
  • A comprehensive workup including CT scan and bone marrow biopsy was negative and a diagnosis of NKTL-NT with a primary cutaneous involvement was made.
  • The patient was free of disease under multi-agent chemotherapy after 24 months of follow-up.
  • [MeSH-major] Killer Cells, Natural / pathology. Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, CD45 / analysis. Antigens, CD56 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Follow-Up Studies. Humans. Leg. Lymphedema / diagnosis. Male

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 S. Karger AG, Basel.
  • (PMID = 17135744.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD56; EC 3.1.3.48 / Antigens, CD45
  • [Number-of-references] 12
  •  go-up   go-down


21. Madray MM, Greene JF Jr, Butler DF: Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Neurol; 2008 Oct;65(10):1378-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To report the association of the development of a primary, cutaneous, anaplastic large-cell lymphoma after initiation of glatiramer acetate treatment of a patient with relapsing-remitting multiple sclerosis.
  • Patient A 33-year-old white woman developed an erythematous nodule on her leg 4 months after starting treatment with glatiramer acetate.
  • Intervention Radiation therapy induced a complete remission.
  • CONCLUSIONS: Several T-cell-mediated skin conditions have been associated with the use of glatiramer acetate, such as pseudolymphoma, drug eruptions, and erythema nodosum.
  • [MeSH-major] Immunosuppression / adverse effects. Immunosuppressive Agents / adverse effects. Leg / pathology. Lymphoma, Large-Cell, Anaplastic / chemically induced. Peptides / adverse effects. Skin Neoplasms / chemically induced
  • [MeSH-minor] Adult. Antigens, CD30 / biosynthesis. Biomarkers. Biopsy. Female. Glatiramer Acetate. Humans. Multiple Sclerosis, Relapsing-Remitting / drug therapy. Neoplasm, Residual. Radiotherapy. Treatment Outcome

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18852356.001).
  • [ISSN] 1538-3687
  • [Journal-full-title] Archives of neurology
  • [ISO-abbreviation] Arch. Neurol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Biomarkers; 0 / Immunosuppressive Agents; 0 / Peptides; 5M691HL4BO / Glatiramer Acetate
  •  go-up   go-down


22. Nikkels AF, Thirion L, Quatresooz P, Piérard GE: Photodynamic therapy for cutaneous verrucous carcinoma. J Am Acad Dermatol; 2007 Sep;57(3):516-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy for cutaneous verrucous carcinoma.
  • This rare neoplasm follows a seemingly indolent progression and exhibits a low metastatic potential.
  • Photodynamic therapy relies on the selective intratumoral cell accumulation and photoactivation of a photosensitizer, leading to the generation of phototoxic compounds responsible for necrosis and apoptosis of the target cells.
  • An 82-year-old man presenting with a large long-standing verrucous carcinoma on the leg was treated successfully by 6 photodynamic therapy sessions administered at weekly intervals using methyl-aminolevulinate and 57-J/cm(2) irradiations at 634-nm wavelength.
  • The use of methyl-aminolevulinate-photodynamic therapy for treating cutaneous verrucous carcinoma had not been reported so far.
  • It may represent a convenient therapeutic alternative in this setting.
  • [MeSH-major] Carcinoma, Verrucous / drug therapy. Leg Dermatoses / drug therapy. Photochemotherapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged, 80 and over. Aminolevulinic Acid / administration & dosage. Aminolevulinic Acid / analogs & derivatives. Aminolevulinic Acid / therapeutic use. Chronic Disease. Drug Administration Schedule. Humans. Male. Photosensitizing Agents / administration & dosage. Photosensitizing Agents / therapeutic use. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434646.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / methyl 5-aminolevulinate; 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


23. Bacro TR, Holladay EB, Stith MJ, Maize JC, Smith CM: Iontophoresis treatment of basal cell carcinoma with cisplatin: a case report. Cancer Detect Prev; 2000;24(6):610-9
Hazardous Substances Data Bank. EPINEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Iontophoresis treatment of basal cell carcinoma with cisplatin: a case report.
  • Iontophoresis is a process that uses electrical current to increase the flux of ionized substances through tissue.
  • The present case report describes the successful treatment of a 67-year-old male with a histologically confirmed BCC on his upper anterolateral left leg.
  • The treatment consisted of four cycles of five successive days of cisplatin iontophoresis, with a 2-week rest period between cycles.
  • The effectiveness of the treatment was confirmed by post-treatment biopsies, which revealed granulation tissue scarring without evidence of BCC.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Carcinoma, Basal Cell / drug therapy. Cisplatin / administration & dosage. Iontophoresis. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Cell Cycle. Drug Administration Schedule. Drug Evaluation. Epinephrine / administration & dosage. Flow Cytometry. Humans. Ki-67 Antigen / analysis. Leg. Male. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11198275.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; Q20Q21Q62J / Cisplatin; YKH834O4BH / Epinephrine
  •  go-up   go-down


24. Kroon HM, Lin DY, Kam PC, Thompson JF: Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg; 2009 Jun;249(6):1008-13
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.
  • INTRODUCTION: The treatment of elderly patients with advanced metastatic melanoma confined to a limb remains controversial.
  • Isolated limb infusion (ILI) is an effective minimally invasive alternative to isolated limb perfusion (ILP) and is therefore a potentially valuable therapeutic option for this group.
  • The patient characteristics in both groups were comparable except that the older group comprised more women (71% vs. 54%; P = 0.02) and had a lower body mass index (median: 24.4 vs. 26.4; P = 0.008).
  • Older patients experienced less limb toxicity after the procedure (Wieberdink grade III/IV toxicity in 36%) compared with younger patients (51%; P = 0.009) while systemic toxicity, complications, and long-term morbidity were similar.
  • CONCLUSIONS: Elderly patients with advanced metastatic melanoma of the limb experience the same or lower toxicity after ILI compared with younger patients while response rates, limb recurrence free interval, survival, and morbidity are similar.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / drug therapy. Melanoma / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Arm. Cohort Studies. Female. Humans. Hyperthermia, Induced. Infusions, Intra-Arterial. Leg. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474677.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


25. Spugnini EP, Citro G, Dotsinsky I, Mudrov N, Mellone P, Baldi A: Ganglioneuroblastoma in a cat: a rare neoplasm treated with electrochemotherapy. Vet J; 2008 Nov;178(2):291-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ganglioneuroblastoma in a cat: a rare neoplasm treated with electrochemotherapy.
  • Physical examination revealed a 1x2x1cm mass originating from a footpad of the right hind leg.
  • A diagnosis of ganglioneuroblastoma was suggested by the tumour appearance following histopathological staining with haematoxylin and eosin and haematoxylin/van Gieson.
  • Immunohistochemical staining for glial fibrillary acidic protein (GFAP), vimentin, neuron-specific enolase (NSE), neurofilament and S100 further confirmed the diagnosis.
  • The tumour had completely regressed within 1 week of the third ECT application and remained in remission for 402 days at which time a small recurrence was noted.
  • Electrochemotherapy is considered a safe and effective treatment for localised neoplasms of cats and dogs and warrants further investigation.
  • [MeSH-major] Cat Diseases / drug therapy. Electrochemotherapy / veterinary. Ganglioneuroblastoma / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Cats. Male

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17910926.001).
  • [ISSN] 1090-0233
  • [Journal-full-title] Veterinary journal (London, England : 1997)
  • [ISO-abbreviation] Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


26. Lacouture ME, Baron JM, Jani AB, Laumann AE, Soltani K: Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody. Clin Exp Dermatol; 2005 Jan;30(1):46-8
Hazardous Substances Data Bank. RITUXIMAB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of radiation-relapsing primary cutaneous B-cell lymphoma with an anti-CD20 monoclonal antibody.
  • Primary cutaneous B cell lymphomas have a high recurrence rate after treatment with surgery and/or local radiation therapy.
  • Both patients had a complete response with no recurrence at follow-up at 17 and 24 months for the large B-cell lymphoma of the leg and the follicle centre cell lymphoma, respectively.
  • These are two of the few cases in the literature showing that rituximab is an effective and well-tolerated treatment for radiotherapy-relapsing primary cutaneous B cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy. Neoplasm Recurrence, Local / prevention & control. Skin Neoplasms / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antigens, CD20 / metabolism. Humans. Male. Middle Aged. Retreatment. Rituximab. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15663503.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, CD20; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


27. Dodd LG, Major N, Brigman B: Malignant giant cell tumor of soft parts. Skeletal Radiol; 2004 May;33(5):295-9
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The patient presented with a fungating skin and soft tissue mass and concurrent pulmonary nodules.
  • [MeSH-major] Giant Cell Tumors / pathology. Leg / pathology. Lung Neoplasms / diagnosis. Osteosarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Biopsy / methods. Diagnosis, Differential. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Neoplasm Recurrence, Local. Rare Diseases / drug therapy. Rare Diseases / pathology. Rare Diseases / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Feb;24(2):248-56 [10680893.001]
  • [Cites] J Pathol. 1972 May;107(1):27-39 [4262633.001]
  • [Cites] Cancer. 1981 Feb 15;47(4):736-47 [7226022.001]
  • [Cites] Cancer. 1972 Jun;29(6):1518-29 [5031245.001]
  • [Cites] Am J Dermatopathol. 1989 Jun;11(3):197-201 [2658646.001]
  • [Cites] Mod Pathol. 1999 Sep;12 (9):894-902 [10496598.001]
  • [Cites] Am J Surg. 1978 Jul;136(1):102-6 [277073.001]
  • [Cites] Cancer. 1977 Jul;40(1):244-53 [195704.001]
  • (PMID = 14997349.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


28. Murata R, Siemann DW, Overgaard J, Horsman MR: Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiother Oncol; 2001 Aug;60(2):155-61
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: A C3H mouse mammary carcinoma transplanted in the foot of CDF1 mice and the KHT mouse sarcoma growing in the leg muscle of C3H/HeJ mice were used.
  • CA4DP enhanced radiation damage in both tumor types.
  • In the KHT sarcoma this enhancement was independent of whether the drug was given before or after irradiating, whereas for C3H mammary carcinoma the enhancement was only significant when administered at the same time or after the radiation, with no enhancement seen if CA4DP was given before.
  • These effects were drug-dose dependent.
  • CA4DP did not enhance radiation damage in normal skin.
  • CONCLUSIONS: CA4DP enhanced radiation damage in the two tumor models without enhancing normal tissue damage.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / therapeutic use. Mammary Neoplasms, Experimental / drug therapy. Mammary Neoplasms, Experimental / radiotherapy. Sarcoma, Experimental / drug therapy. Sarcoma, Experimental / radiotherapy. Stilbenes / therapeutic use
  • [MeSH-minor] Animals. Combined Modality Therapy. Mice. Mice, Inbred C3H. Necrosis. Neoplasm Transplantation

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11439210.001).
  • [ISSN] 0167-8140
  • [Journal-full-title] Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • [ISO-abbreviation] Radiother Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA84408
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Stilbenes; I5590ES2QZ / fosbretabulin
  •  go-up   go-down


29. Roberts MS, Wu ZY, Siebert GA, Anissimov YG, Thompson JF, Smithers BM: Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy. Melanoma Res; 2001 Aug;11(4):423-31
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has a lower morbidity in treating localized recurrences and in transit metastases of the limb for tumours such as melanoma, Merkel cell tumour and Kaposi's sarcoma, allowing administration of high concentrations of cytotoxic agent to the affected limb under hypoxic conditions.
  • Melphalan is the preferred cytotoxic agent for the treatment of melanoma by ILP or ILI.
  • The kinetics of drug distribution in the limb was calculated using a two-compartment vascular model, where both tissue and infusate act as well-stirred compartments.
  • Recirculation and wash-out flow rates, tissue concentrations and the permeability surface area product (PS) were calculated.
  • Correlations between the PS value and the drug concentrations in the perfusate and tissue were supported by the results.
  • These data contribute to a better understanding of the distribution of melphalan during ILI in the limb, and offer the opportunity to optimize the drug regimen for patients undergoing ILI.
  • [MeSH-major] Infusion Pumps. Leg. Melphalan / pharmacokinetics. Melphalan / therapeutic use. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / pharmacokinetics. Antineoplastic Agents, Alkylating / therapeutic use. Carcinoma, Merkel Cell / drug therapy. Carcinoma, Merkel Cell / pathology. Dose-Response Relationship, Drug. Female. Humans. Male. Melanoma / drug therapy. Melanoma / pathology. Middle Aged. Models, Biological. Sarcoma, Kaposi / drug therapy. Sarcoma, Kaposi / pathology. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11479432.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


30. Grünhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, Eggermont AM: Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol; 2005 Aug;12(8):609-15
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Isolated limb perfusion (ILP) is an effective treatment modality for multiple in-transit melanoma metastases confined to the limb.
  • Recurrences after ILP, however, occur in approximately 50% of patients and are a challenge for further treatment.
  • Out of 100 tumor necrosis factor (TNF)-based ILPs with TNF and melphalan (TM-ILPs) in melanoma patients between March 1991 and July 2003, 25 repeat ILP procedures were performed in 21 patients in whom prior ILP treatment failed.
  • All patients had bulky and/or numerous lesions and were treated with mild hyperthermic TM-ILP by using 2 to 4 mg of TNF and 10 to 13 mg/L of limb volume for the leg and arm, respectively.
  • Local recurrence occurred in 72%; the median time to local progression was 14 months.
  • CONCLUSIONS: Patients who experience treatment failure after previous ILP treatment respond very well to repeat perfusion, and prolonged local control can thus be obtained.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Melphalan / administration & dosage. Neoplasm Seeding. Skin Neoplasms / drug therapy. Tumor Necrosis Factor-alpha / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Arm. Disease Progression. Drug Therapy, Combination. Female. Humans. Leg. Male. Middle Aged. Retreatment. Treatment Failure

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15968498.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Tumor Necrosis Factor-alpha; Q41OR9510P / Melphalan
  •  go-up   go-down


31. Noorda EM, Vrouenraets BC, Nieweg OE, Van Coevorden F, Kroon BB: Isolated limb perfusion: what is the evidence for its use? Ann Surg Oncol; 2004 Sep;11(9):837-45
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Following the principles of Evidence-Based Medicine, we reviewed the best available evidence for isolated limb perfusion (ILP) for melanoma and soft tissue sarcoma (STS) of the limb.
  • Therapeutic M-ILP, with or without tumor-necrosis factor alpha and interferon gamma (T(I)M-ILP), seems indicated in unresectable melanoma (level 3 to 4 evidence).
  • A comparison of level 3 to 4 studies on ILP and other neoadjuvant treatment modalities for unresectable STS shows that ILP results in the highest limb salvage rate with the lowest complication rate.
  • ILP seems the most effective limb sparing, neoadjuvant treatment modality when compared with other neoadjuvant treatment options for unresectable STS of the limb (level 3 to 4 evidence), although randomized studies are lacking.
  • [MeSH-major] Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Sarcoma / drug therapy. Skin Neoplasms / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Arm. Evidence-Based Medicine. Humans. Leg. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Prognosis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15313738.001).
  • [ISSN] 1068-9265
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  •  go-up   go-down


32. Guadagni S, Russo F, Rossi CR, Pilati PL, Miotto D, Fiorentini G, Deraco M, Santinami M, Palumbo G, Valenti M, Amicucci G: Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma. Am J Surg; 2002 Jan;183(1):28-36
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Deliberate hypoxic pelvic and limb chemoperfusion in the treatment of recurrent melanoma.
  • BACKGROUND: The treatment of patients with advanced or recurrent pelvic melanoma, which are often associated with lesions in the lower limbs, is still unsatisfactory and controversial.
  • A simplified hypoxic pelvic and limb perfusion has been recently recommended to provide therapeutic options for palliation and possibly cure.
  • Response rate and time to disease progression were the primary endpoints; overall survival was the secondary endpoint.
  • Median time to disease progression was 12 months (range 9 to 30 months).
  • CONCLUSIONS: Hypoxic pelvic and limb perfusion is a safe and good palliative treatment for patients with unresectable recurrent melanoma.
  • [MeSH-major] Anoxia. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Melanoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Dacarbazine / administration & dosage. Disease Progression. Disease-Free Survival. Epirubicin / administration & dosage. Female. Hemodynamics. Humans. Leg / pathology. Male. Melphalan / administration & dosage. Middle Aged. Palliative Care. Pelvis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11869699.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 7GR28W0FJI / Dacarbazine; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


33. Bula P, Bula-Sternberg J, Wollina U, Haroske G, Bonnaire F: [Marjolin's ulcer: malignant transformation of a crural ulcer due to posttraumatic chronic osteomyelitis]. Unfallchirurg; 2010 Feb;113(2):149-54
MedlinePlus Health Information. consumer health - Leg Injuries and Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on the case of an 81-year-old female patient who developed a squamous cell carcinoma in a long-lasting therapy-resistant crural ulcer of the lower leg due to posttraumatic chronic osteomyelitis.
  • Eventually the lower leg had to be amputated because of massive destruction of soft tissue and the tibia bone.
  • [MeSH-major] Amputation. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Cell Transformation, Neoplastic / pathology. Leg Injuries / pathology. Leg Injuries / surgery. Leg Ulcer / pathology. Leg Ulcer / surgery. Osteomyelitis / pathology. Osteomyelitis / surgery. Pseudomonas Infections / pathology. Pseudomonas Infections / surgery. Pseudomonas aeruginosa. Skin Ulcer / pathology. Tibia / surgery. Wounds, Penetrating / pathology. Wounds, Penetrating / surgery
  • [MeSH-minor] Aged, 80 and over. Artificial Limbs. Chronic Disease. Disease Progression. Drug Resistance, Bacterial. Female. Humans. Magnetic Resonance Imaging. Neoplasm Staging. Skin / pathology

  • Genetic Alliance. consumer health - Osteomyelitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Orthop Relat Res. 1999 May;(362):181-9 [10335297.001]
  • [Cites] J South Orthop Assoc. 1999 Fall;8(3):181-7 [12132863.001]
  • [Cites] Rev Rhum Engl Ed. 1996 Jan;63(1):62-4 [9064114.001]
  • [Cites] J Dtsch Dermatol Ges. 2008 Jul;6(7):569-72 [18248496.001]
  • [Cites] Br J Dermatol. 1995 Oct;133(4):571-4 [7577586.001]
  • [Cites] Acta Orthop Belg. 1993;59(4):327-32 [8116362.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2007 Aug;21(7):935-41 [17659003.001]
  • [Cites] Adv Dermatol. 1987;2:19-46 [3079255.001]
  • [Cites] Arch Dermatol. 1992 Nov;128(11):1486-9 [1444502.001]
  • [Cites] Med J Aust. 1996 Jun 17;164(12):718-20 [8668077.001]
  • [Cites] South Med J. 2005 Oct;98(10):1053 [16295826.001]
  • [Cites] Dermatol Online J. 2007 May 01;13(2):27 [17498446.001]
  • [Cites] Indian J Cancer. 1996 Sep;33(3):139-44 [9055488.001]
  • [Cites] J Burn Care Rehabil. 1990 Sep-Oct;11(5):460-9 [2246317.001]
  • [Cites] Int J Dermatol. 1991 Jan;30(1):58-61 [1993569.001]
  • [Cites] Int Orthop. 2001;25(6):389-91 [11820449.001]
  • [Cites] J Foot Surg. 1981 Fall;20(3):136-41 [7276451.001]
  • [Cites] J Bone Joint Surg Am. 1990 Jan;72(1):12-8 [2295659.001]
  • [Cites] J Clin Pathol. 1963 Nov;16:573-80 [14076377.001]
  • [Cites] Ann Dermatol Venereol. 1993;120(10):675-8 [8161096.001]
  • [Cites] Orthop Rev. 1991 Jul;20(7):625-8 [1945509.001]
  • [Cites] Ann Surg. 1981 May;193(5):598-605 [7235765.001]
  • [Cites] J Dermatol Surg Oncol. 1994 Feb;20(2):141-3 [8113507.001]
  • [Cites] J Mal Vasc. 2001 Apr;26(2):85-91 [11319413.001]
  • [Cites] Clin Orthop Relat Res. 1985 Sep;(198):264-7 [4028559.001]
  • [Cites] Dermatol Surg. 1996 Dec;22(12):1015-8 [9078313.001]
  • [Cites] J Natl Cancer Inst. 1992 Feb 19;84(4):235-41 [1734084.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 2007 Feb;93(1):63-71 [17389826.001]
  • [Cites] Skeletal Radiol. 2001 Jun;30(6):331-7 [11465774.001]
  • [Cites] Arch Phys Med Rehabil. 1986 Nov;67(11):831-3 [3778183.001]
  • (PMID = 19859679.001).
  • [ISSN] 1433-044X
  • [Journal-full-title] Der Unfallchirurg
  • [ISO-abbreviation] Unfallchirurg
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


34. von Nida J, Quirk C: Successful treatment of in-transit melanoma metastases using topical 2-4 dinitrochlorobenzene. Australas J Dermatol; 2003 Nov;44(4):277-80
Hazardous Substances Data Bank. 1-CHLORO-2,4-DINITROBENZENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of in-transit melanoma metastases using topical 2-4 dinitrochlorobenzene.
  • A 78-year-old woman presented with multiple histologically proven in-transit melanoma metastases involving the lower half of the left leg.
  • Initial therapy with liquid nitrogen cryotherapy had some short-lived success but was not tolerated by the patient.
  • During the first 2 years of therapy a partial response was achieved, with treated lesions regressing while new lesions developed.
  • This treatment did not prevent metastatic lymph node and ultimately fatal liver involvement.
  • Topical immunotherapy can be a useful adjunct in the treatment of cutaneous melanoma metastases, particularly in those patients who are unable to tolerate other destructive modalities of therapy.
  • [MeSH-major] Dinitrochlorobenzene / administration & dosage. Melanoma / drug therapy. Melanoma / secondary. Neoplasms, Unknown Primary / pathology. Skin Neoplasms / drug therapy. Skin Neoplasms / secondary
  • [MeSH-minor] Administration, Topical. Aged. Biopsy, Needle. Combined Modality Therapy. Disease Progression. Fatal Outcome. Female. Humans. Immunohistochemistry. Immunosuppressive Agents / administration & dosage. Immunotherapy / methods. Neoplasm Staging. Risk Assessment

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14616496.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; GE3IBT7BMN / Dinitrochlorobenzene
  •  go-up   go-down


35. Tran N, Krueger T, Pan Y, Yan H, Cheng C, Altermatt HJ, Ballini JP, Borle F, Ris HB, Andrejevic-Blant S: Correlation of photodynamic activity and fluorescence signaling for free and pegylated mTHPC in mesothelioma xenografts. Lasers Surg Med; 2007 Mar;39(3):237-44
MedlinePlus Health Information. consumer health - Mesothelioma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY DESIGN/MATERIALS AND METHODS: Twelve animals received light delivery (20 J/cm(2), 150 mW/cm(2), spot size 1.2 cm) on the tumor and the hind leg 3 days after sensitization with 0.15 mg/kg free mTHPC (n = 6) or equimolar-dosed pegylated mTHPC (n = 6).
  • RESULTS: Pegylated mTHPC resulted in a similar extent of PDT-related tumor necrosis but in lower skin phototoxicity than free mTHPC.
  • Pegylated mTHPC revealed a higher tumor to skin fluorescence intensity ratio than free mTHPC (P<0.001).
  • [MeSH-major] Mesoporphyrins / pharmacology. Mesothelioma / drug therapy. Photochemotherapy. Photosensitizing Agents / pharmacology. Pleural Neoplasms / drug therapy
  • [MeSH-minor] Animals. Female. Mice. Mice, Nude. Microscopy, Fluorescence. Necrosis. Neoplasm Transplantation. Transplantation, Heterologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc
  • (PMID = 17345623.001).
  • [ISSN] 0196-8092
  • [Journal-full-title] Lasers in surgery and medicine
  • [ISO-abbreviation] Lasers Surg Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


36. Ingen-Housz-Oro S, Bagot M: [Cutaneous lymphomas]. Rev Prat; 2009 Nov 20;59(9):1207-15
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cutaneous lymphomas are lymphoproliferations affecting skin only at the time of diagnosis.
  • There are two major types, B-cell lymphomas and T-cell lymphomas, which prognosis depends of histological subtype and staging evaluation.
  • In cutaneous B-cell lymphomas, there are two indolent subtypes (primary cutaneous marginal zone B-cell lymphoma and primary cutaneous follicle center lymphoma) and one more aggressive type (primary cutaneous diffuse large B-cell lymphoma, leg type).
  • Staging evaluation with CT-scan of chest, abdomen and pelvis, bone marrow examination if necessary and lymph node biopsy if palpable node over 1 or 1.5 cm diameter, is necessary for therapeutic decision.
  • [MeSH-major] Lymphoma. Skin Neoplasms
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Immunohistochemistry. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / radiography. Lymphoma, B-Cell / radiotherapy. Lymphoma, B-Cell / surgery. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiography. Lymphoma, T-Cell / radiotherapy. Lymphoma, T-Cell / surgery. Mycosis Fungoides / diagnosis. Mycosis Fungoides / radiography. Neoplasm Staging. Prognosis. Radiography, Abdominal. Radiography, Thoracic. Sezary Syndrome / diagnosis. Sezary Syndrome / pathology. Sezary Syndrome / radiography. Skin / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19961071.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 16
  •  go-up   go-down


37. Raymond AK, Puri PK, Selim MA, Tyler DS, Nelson KC: Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb. Arch Dermatol; 2010 Dec;146(12):1438-9
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Benzenesulfonates / adverse effects. Carcinoma, Squamous Cell / chemically induced. Melanoma / drug therapy. Pyridines / adverse effects. Skin Neoplasms / chemically induced
  • [MeSH-minor] Aged. Drug Administration Routes. Follow-Up Studies. Humans. Leg. Male. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Receptors, Vascular Endothelial Growth Factor

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21173337.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / TL1RR024126
  • [Publication-type] Case Reports; Letter; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor
  •  go-up   go-down


38. Kroon BB, Noorda EM, Vrouenraets BC, Nieweg OE: Isolated limb perfusion for melanoma. J Surg Oncol; 2002 Apr;79(4):252-5
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Melanoma / drug therapy. Melphalan / administration & dosage. Skin Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Leg. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920783.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  • [Number-of-references] 7
  •  go-up   go-down


39. Wolf IH, Smolle J, Binder B, Cerroni L, Richtig E, Kerl H: Topical imiquimod in the treatment of metastatic melanoma to skin. Arch Dermatol; 2003 Mar;139(3):273-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical imiquimod in the treatment of metastatic melanoma to skin.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Melanoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Skin Neoplasms / drug therapy
  • [MeSH-minor] Administration, Cutaneous. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Combined Modality Therapy. Dacarbazine / administration & dosage. Female. Humans. Interferon-alpha / therapeutic use. Knee. Leg. Lymphatic Metastasis. Male. Middle Aged. Nitrosourea Compounds / administration & dosage. Organophosphorus Compounds / administration & dosage. Recombinant Proteins. Scalp. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. Fotemustine .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12622616.001).
  • [ISSN] 0003-987X
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Nitrosourea Compounds; 0 / Organophosphorus Compounds; 0 / Recombinant Proteins; 7GR28W0FJI / Dacarbazine; 99011-02-6 / imiquimod; 99210-65-8 / interferon alfa-2b; BG3F62OND5 / Carboplatin; GQ7JL9P5I2 / fotemustine
  •  go-up   go-down






Advertisement